Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma

Completed · Phase 2

Conditions studied: Non-Hodgkin's Lymphoma

In brief

Primary Objective: Evaluate the clinical activity of the RT-PEPC combination regimen (rituximab, thalidomide, and prednisone, etoposide, procarbazine, cyclophosphamide) in patients with relapsed mantle cell lymphoma. Specifically, response rate (RR) and time to disease progression (TTP) will be assessed. Secondary Objectives: 1. Assess the toxicity profiles of RT-PEPC treatment in patients with relapsed mantle cell lymphoma. 2. Prospectively characterize the angiogenic profile of patients with mantle cell lymphoma during treatment with RT-PEPC. The dynamics of the angiogenic profile will be correlated with clinical response to RT-PEPC therapy. 3. Assess the quality of life of patients receiving RT-PEPC treatment

Key facts

Study ID

NCT00151281

Run by

Weill Medical College of Cornell University

People needed

25

Starts

2004-11-01

Expected to finish

2011-04-07

Last updated by the study team

2018-06-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed diagnosis of mantle cell Non-Hodgkin's Lymphoma with characteristic immunophenotypic profiles: CD5(+),CD23(-), CD19(+) or CD20(+), cyclin D1(+), and CD10(-)
• Patient has persistent / recurrent disease after standard chemotherapy
• Patient has not received either standard or investigational drugs within the last 3 weeks
• Available frozen tumor tissue obtained since completion of last prior therapy (rebiopsy if needed)
• Patient has measurable disease as defined by a tumor mass > 1.5 cm in one dimension
• Age > 18 years
• Absolute granulocyte count > 1000 cells/mm3
• Platelet count > 50,000 cells/mm3
• Creatinine < 2.0 x ULN
• Total bilirubin < 2.0 x ULN
• Patient has KPS > 50%
• Patient agrees to use birth control if of reproductive potential

You may not qualify if…

• Known central nervous system (CNS) involvement by lymphoma
• Known HIV disease
• Known peripheral neuropathy > grade 2
• Patient is pregnant or nursing
• Patient has had major surgery within the last 3 weeks
• Patient is receiving other investigational drugs

Where it is running

• Weill Medical College of Cornell University — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.